Elan, Biogen launch Tysabri trial in oncology
DUBLIN, Sept 5 |
DUBLIN, Sept 5 (Reuters) - Biogen Idec (BIIB.O) and Elan Corp (ELN.I) have launched the first clinical trial of their multiple sclerosis drug Tysabri for patients with relapsed or refractory multiple myeloma, the companies said on Friday.
The first dose was administered on Thursday, they said.
Multiple myeloma is a cancer of the plasma cell. (Reporting by Jonathan Saul; Editing by Quentin Bryar)
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters